Report International

03/02/2026

Congratulations to our colleagues in on their recent publication in JCI Insight, which provides additional insight into immunity and progression to active tuberculosis disease. Advancing our understanding of host immune responses remains central to improving prediction, prevention, and treatment strategies for TB.

🔗 Read the article: https://insight.jci.org/articles/view/202134

03/01/2026

Join us in congratulating Dr Rajita Bhavaraju on her Lifetime Achievement Award! Click on link to read more!

https://reportinternational.org/celebrating-dr-rajita-r-bhavaraju/

02/27/2026

Childhood tuberculosis remains underdiagnosed and is frequently under- or overtreatment compared to adult TB. The Shortened Regimen for Drug-Susceptible TB in Children (SMILE-TB) trial, led by the SMART4TB Consortium and funded by the U.S. government, is evaluating a shorter treatment regimen for children with pulmonary and lymph node TB. This work addresses a critical gap in pediatric TB care and aims to improve treatment tolerability and outcomes.

🔗 Learn more:https://tbcenter.jhu.edu/wp-content/uploads/2025/12/SMILE-TB-Study.pdf

02/25/2026

The Atlas of TB Innovations aims to serve as a centralized, evolving reference for scientific, technological, and operational advancements in tuberculosis. By cataloguing innovations as they progress from development through implementation and regulatory review, the Atlas seeks to provide transparency on effectiveness, reliability, and global uptake.

🔗 Explore the Atlas: https://www.atlasoftbinnovations.in/

Welcome to India Innovation Summit - Pioneering solutions to End TB

02/23/2026

New TB vaccines will require more than scientific advancement; they will depend on trusted community engagement and equitable implementation. "What Could Go Right: Vital Partnerships with Communities and Civil Society for New Tuberculosis Vaccines," developed with community partners and supported by Wellcome, examines how civil society organizations help build the “infrastructures of trust” necessary for vaccine acceptance, demand, and access.

🔗 Learn more: https://www.treatmentactiongroup.org/publication/what-could-go-right-vital-partnerships-for-new-tuberculosis-vaccines/

What Could Go Right: Vital Partnerships with Communities and Civil Society for New Tuberculosis Vaccines, written together with community partners and supported by Wellcome, explores the indispensable role of communities and civil society in preparing the way for new TB vaccines and ensuring their s...

02/20/2026

The World Health Organization has released updated recommendations on HIV clinical management, including revised guidance on antiretroviral therapy, management of vertical HIV transmission, and tuberculosis prevention for people living with HIV. These recommendations reinforce an evidence-based and cost-effective approach to improving treatment outcomes, reducing HIV-related mortality, and accelerating progress toward ending AIDS as a public health threat.

🔗 Read more: https://www.who.int/news/item/07-01-2026-who-releases-updated-recommendations-on-hiv-clinical-management

The World Health Organization (WHO) has released updated recommendations on HIV clinical management providing new and revised guidance on antiretroviral therapy, management of vertical HIV transmission, and tuberculosis (TB) prevention for people living with HIV. These recommendations support an evi...

02/18/2026

Public health has been shaped by leaders whose strategies transformed global health outcomes. William H. Foege played a central role in advancing smallpox vaccination strategy, contributing to one of the most successful disease eradication efforts in history. His work demonstrated the power of surveillance, targeted intervention, and coordinated global action.

As tuberculosis remains the world’s leading infectious disease killer, the field continues to seek similarly transformative breakthroughs in strategy, implementation, and equity.

🔗 Read more: https://www.nytimes.com/2026/01/24/us/william-h-foege-dead.html?smid=em-share

His containment strategy helped wipe out the disease in the 1970s, one of the world’s greatest public health triumphs. He also led the C.D.C. and promoted childhood vaccination worldwide.

02/16/2026

There is still time to register for the Annual TB Conference hosted by the The Union North America Region. This meeting convenes clinicians, researchers, and public health professionals committed to advancing tuberculosis prevention, diagnosis, and treatment across the region.

Registration closes February 28, 2026 at 4:59 p.m. 🔗 Learn more and register: https://bclung.ca/lung-health/tuberculosis/annual-tb-conference-the-union-nar/

Annual TB Conference – The Union NARThe Union-North America Region (NAR) is the regional arm of the International Union against Tuberculosis and Lung Disease (The Union), a global public health organization with the vision to provide health solutions to the poor. BC Lung is an organizational membe...

02/16/2026

We’re happy to share our February Newsletter with you!

https://reportinternational.org/wp-content/uploads/2026/02/RePORT-February-2026-Newsletter.pdf

02/03/2026

Did you know the theme for the 2026 World World TB Day? just announced the theme!

01/16/2026

Antimicrobial stewardship (AMS) focuses on the evidence-based and responsible use of anti-infective agents to improve patient outcomes and limit resistance. Recent work highlights how TB is increasingly being incorporated into AMS models, supporting more coordinated, data-driven approaches to TB treatment and programmatic decision-making.

Read more: https://medicalxpress.com/news/2026-01-clinical-standards-antimicrobial-stewardship-tuberculosis.html

Antimicrobial stewardship (AMS) refers to coordinated strategies for the targeted, evidence-based, and safe use of anti-infective agents. The aim is to improve treatment outcomes, minimize side effects, and prevent the development and spread of antimicrobial resistance. While AMS is well established...

01/14/2026

New findings provide additional evidence that treating tuberculosis with multiple drugs can more effectively inhibit Mycobacterium tuberculosis, including drug-resistant strains. By targeting bacteria through complementary mechanisms, combination regimens remain central to overcoming resistance and improving treatment outcomes.

Learn more: https://www.rockefeller.edu/news/38777-this-new-one-two-punch-could-knock-out-drug-resistant-tb/

Tuberculosis is both curable and preventable, yet each year, it still kills more people than any other infectious disease. One reason is that current treatments hinge on rifampicin, an antibiotic that blocks bacterial transcription and forms the cornerstone of a multidrug regimen—and rising drug r...